BIAF vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 13, 2026

BIAF

39.2
AI Score
VS
BIAF Wins

CDNA

23.1
AI Score

Investment Advisor Scores

BIAF

39score
Recommendation
SELL

CDNA

23score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIAF CDNA Winner
Revenue 2.86M 249.65M CDNA
Net Income -7.00M 113.44M CDNA
Net Margin -244.5% 45.4% CDNA
Operating Income -6.95M 114.42M CDNA
ROE -185.6% 26.7% CDNA
ROA -91.8% 21.3% CDNA
Total Assets 7.62M 532.99M CDNA
Cash 2.43M 373.64M CDNA
Current Ratio 1.44 4.58 CDNA
Free Cash Flow -6.52M 29.26M CDNA

Relative Price Performance (Last 90 Days)

BIAF 1M: -40.1% · 3M: -75.3% CDNA 1M: +29.2% · 3M: +125.4%

Current Technical Phase

BIAF

Markdown
Sell / avoid

Price below a falling SMA50 (slope -40.0%), weak momentum, RSI 29

RSI (14): 28.8 · Price: $0.40

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (34.1% over 20 days), RSI 72

RSI (14): 71.8 · Price: $48.61

Fundamentals Snapshot

Metric BIAF CDNA
Market Cap
Forward P/E -0.1 35.9
Trailing P/E 22.4
Revenue (TTM)
Revenue Growth 0.2% 0.5%
Gross Margin 0.3% 0.7%
Operating Margin -2.2% 0.0%
EPS -0.09 2.10
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BIAF is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.